Abstract
Purpose Varying degrees of macular ischemia generally occur in diabetic retinopathy (DR). This study aims to evaluate the effect of conbercept with 3+ pro re nata (PRN) on macular perfusion status in patients with diabetic macular edema (DME) and quantitatively assess changes in foveal avascular zone (FAZ) areas and capillary density in macular regions by applying OCT angiography (OCTA). Methods Fifty patients were divided into ischemic (n=31) and non-ischemic (n=19) groups according to the presence of ischemia on OCTA at baseline. All patients received interval injection of 0.5mg of conbercept with 3+ PRN principle. The FAZ areas and macular vessel density measured using OCTA were evaluated at baseline, 3 months, and 6 months after treatment in both groups. Results At months 3 and 6, the FAZ area in the ischemic group changed from 0.510±0.171mm 2 to 0.441±0.158mm 2 then to 0.427±0.153mm 2 (p=0.003, p=0.296); in the non-ischemic group, it remained stable (p=0.269, p=0.926). The superficial vessel density changed from 41.1%±4.1% to 42.5%±4.7% then to 42.6%±4.6% (p=0.043, p=0.812), and the deep vessel density changed from 40.7%±4.4% to 42.3%±3.6% then to 42.3%±4.7% (p=0.072, p=0.961) in the ischemic group. In the non-ischemic group, the superficial vessel density changed from 44.8%±3.2% to 46.0%±3.5% then to 45.7%±3.3% (p=0.108, p=0.666), whereas the deep vessel density changed from 43.6%±3.6% to 43.8%±3.2% then to 43.5%±4.5% (p=0.882, p=0.736). Reperfusion in macular nonperfusion areas was observed. Conclusion Anti–vascular endothelial growth factor treatment may have a positive effect on macular perfusion status, improve macular ischemia, and promote reperfusion appearance in patients with DME. Furthermore, OCTA had advantages in quantifying and calculating blood flow index in the study of macular perfusion status.
Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography
